| CAS |
No.68406-26-8 |
| 中文名称 |
人参皂苷Rb3(10mM in DMSO,无菌） |
| 英文名称 |
Ginsenoside Rb3(10mM in DMSO，Sterile） |
| 分子式 |
C53H90O22 |
| 分子量 |
1079.28 |
| 溶解性 |
请根据自己的实验要求使用。 |
| 外观(性状) |
无菌溶液 |
| 储存条件 |
Stroe at -20℃，6 months. |
| 运输条件 |
冷冻运输 |
| 靶点 |
COX-2;iNOS;NF-κB |
| 通路 |
Immunology & Inflammation;NF-κB |
| 背景说明 |
据报道，在 293T 细胞系中 Ginsenoside Rb3 抑制 TNFα 诱导的 NF-κB 转录活性，IC50 为 8.2 μM。Ginsenoside Rb3 还抑制 COX-2 和 iNOS mRNA的诱导。 |
| 生物活性 |
Ginsenoside Rb3 is extracted from steamed Panax ginseng C. A. Meyer. Ginsenoside Rb3 exhibits inhibitory effect on TNFα-induced NF-κB transcriptional activity with an IC50 of 8.2 μM in 293T cell lines. Ginsenoside Rb3 also inhibits the induction of COX-2 and iNOS mRNA.[1-3] |
| In Vitro |
使用人肾 293T 细胞测试 Ginsenosides Rb3 (0.1-10 μM) 对肿瘤坏死因子-α (TNF) 诱导的活化 B 细胞 (NF-κB) 荧光素酶报告基因活性的核因子 kappa-轻链增强子的抑制作用基于测定。Ginsenoside Rb3 显示出显著的活性，IC50 为 8.2 μM。在用 TNF-α (10 ng/mL) 处理 HepG2 细胞后，Ginsenosides Rb3 还以剂量依赖性方式抑制环氧合酶-2 (COX-2) 和诱导型一氧化氮合酶 (iNOS) 信使核糖核酸 (mRNA) 的诱导)[1]。Ginsenoside Rb3 (0.1-10 μM) 以剂量依赖的方式显著增加细胞活力并抑制乳酸脱氢酶 (LDH) 的释放。在细胞暴露于氧气和葡萄糖剥夺 (OGD)/OGD-Rep 后，通过 MTT 还原测定的 PC12 细胞活力也显著降低。但是，当用 Ginsenoside Rb3 (0.1、1 和 10 μM) 预处理细胞时，OGD/OGD-Rep 诱导的细胞毒性显著减弱，人参皂苷 Rb3 处理会以浓度依赖性方式减弱这种毒性。与对照组相比，存活率分别提高到52.8%±5.6%、64.6%±5.7% 和 76.4%±8.8%[2]。 |
| In Vivo |
Ginsenosides Rb3 是从 Gynostemma pentaphyllum 中分离出来的主要化合物，可全面改善 ApcMin/+ 小鼠的肠道微环境并诱导抗息肉病。六周大的小鼠在肠息肉出现之前接受 Ginsenosides Rb3 处理。监测所有小鼠的食物摄入量、水消耗量和体重变化。在整个实验过程中，未观察到与 Rb3/Rd 相关的小鼠体重减轻。此外，没有一只接受过处理的老鼠在食物和水的消耗方面表现出变化。然而，通过 Ginsenosides Rb3 处理，息肉的数量和大小有效减少[3]。 |
| 细胞实验 |
NGF-differentiated PC12 cells are plated at a density of 1.0×105 cells/mL 2 days before each experiment. To initiate OGD， the cell culture medium is removed and replaced with the glucose-free DMEM， then the cells are incubated at 37°C in an oxygen-free chamber (95% N2 and 5% CO2) for 4 h (OGD)， and the change in oxygen levels of the culture medium are monitored during incubation in oxygen-free chamber. Following OGD， glucose is added to normal levels (final concentration: 4.5 mg/mL) and cells are incubated under normal growth conditions (95% air and 5% CO2) for additional 24 h as OGD-reperfusion (OGD-Rep). Ginsenoside Rb3 (0.1， 1， 10 μM) is added to the culture 24 h before OGD treatment and throughout the OGD reperfusion. The control culture is always maintained in normal DMEM and put in the incubator under normal conditions[2]. |
| 动物实验 |
Mice[3]Heterozygous male ApcMin/+ (C57BL/6J-ApcMin/+) mice are used. Total 32 male ApcMin/+ mice (aged 6 weeks) are divided into three groups; 10 mice in the control group and 22 mice equally divided for Rb3 and Rd treatments. The mice are daily gavage with a single dose of Ginsenoside Rb3 or Rd at 20?mg/kg， or solvent control. The treatments are carried out for 8 consecutive weeks. |
| 激酶实验 |
HepG2 cells are seeded at a concentration of 1×105 cells/mL (1.5 mL) in a 12-well plate and grown for 24 h. All cells are then transfected with Pnf-κB-luc plasmid (0.5 μg/well). Transfection are performed by the lipofectamine LTX. After 23 h of transfection， medium is changed to assay medium. After 24 h of transfection， cells are treated with test compounds (e.g.， Ginsenoside Rb3; 0.1， 1 and 10 uM) for another 24 hours. After 25 h of transfection， cells are treated with 10 ng/mL of TNF-α for another 23 hours. The luciferase activity of cell lysates is assayed with 100 μL of by luciferase assay kit using an LB 953 Autolumat. Transfections are performed in triplicate， and activation is normalized against α-galactosidase activity[1]. |
| 数据来源文献 |
[1]. He F， et al. Antitumor effects of dammarane-type saponins from steamed Notoginseng. Pharmacogn Mag. 2014 Jul;10(39):314-7.
[2]. Zhu JR， et al. Protective effects of ginsenoside Rb(3) on oxygen and glucose deprivation-induced ischemic injury in PC12 cells. Acta Pharmacol Sin. 2010 Mar;31(3):273-80.
[3]. Huang G， et al. Ginsenosides Rb3 and Rd reduce polyps formation while reinstate the dysbiotic gut microbiota and the intestinal microenvironment in ApcMin/+ mice. Sci Rep. 2017 Oct 2;7(1):12552. |
| 规格 |
1ml |
| 单位 |
瓶 |
中文
英语
说明书下载
京公网安备 11011202000391号